CT103

  • A T cell therapy targeting desired tumor antigens with a short-cut process. There are quite a lot of advanced cancer patients disqualified for immunotherapies because they display insufficient quality and quantity of immune cells including dendritic cells (DCs). We will provide a universal antigen-presenting cell (APC) bank system to activate T cells ex vivo with desired tumor antigens, which will increase anti-tumor efficacy of T cells. Notably, it only requires limited amount of peripheral blood (e.g. 50mL) for the manufacture. Considered to effectively treat advanced cancer patients, this off-of-shelf APC platform will bypass the allogenic issue, display safety, and innovate a feasible anti-tumor immune cell product.